FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045550424> ?p ?o ?g. }

• W2045550424 endingPage "290" @default.
• W2045550424 startingPage "285" @default.
• W2045550424 abstract "No AccessJournal of UrologyInvestigative Urology1 Jul 2013Dietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma Anaid Benitez, Travis J. Yates, N. Shamaldevi, Tim Bowen, and Vinata B. Lokeshwar Anaid BenitezAnaid Benitez Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida Equal study contribution. More articles by this author , Travis J. YatesTravis J. Yates Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida Equal study contribution. More articles by this author , N. ShamaldeviN. Shamaldevi Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida More articles by this author , Tim BowenTim Bowen Section of Nephrology, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom More articles by this author , and Vinata B. LokeshwarVinata B. Lokeshwar Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida Department of Cell Biology, University of Miami-Miller School of Medicine, Miami, Florida More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.12.011AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Current treatments for metastatic renal cell carcinoma do not extend survival beyond a few months. Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy. Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses of 450 to 3,000 mg per day. Hymecromone inhibits the synthesis of hyaluronic acid, which promotes tumor growth and metastasis. We recently noted that the hyaluronic acid receptors CD44 and RHAMM are potential predictors of metastatic renal cell carcinoma. In the current study we examined the antitumor properties of hymecromone, sorafenib and the combination in renal cell carcinoma models. Materials and Methods: Using proliferation, clonogenic and apoptosis assays, we examined the effects of hymecromone (0 to 32 μg/ml), sorafenib (0 to 3.2 μg/ml) and hymecromone plus sorafenib in Caki-1, 786-O, ACHN and A498 renal cell carcinoma cells, and HMVEC-L and HUVEC endothelial cells. A Boyden chamber was used for motility and invasion assays. Apoptosis indicators, hyaluronic acid receptors, epidermal growth factor receptor and c-Met were evaluated by immunoblot. The efficacy of hymecromone, sorafenib and hymecromone plus sorafenib was assessed in the sorafenib resistant Caki-1 xenograft model. Results: Hymecromone plus sorafenib synergistically inhibited proliferation (greater than 95%), motility/invasion (65%) and capillary formation (76%) in renal cell carcinoma and/or endothelial cells, and induced apoptosis eightfold (p <0.001). Hymecromone plus sorafenib inhibited hyaluronic acid synthesis and adding hyaluronic acid reversed the cytotoxicity of hymecromone plus sorafenib. Hymecromone plus sorafenib up-regulated pro-apoptotic indicators and down-regulated Mcl-1, CD44, RHAMM, phospho-epidermal growth factor receptor and phospho-cMet. In all assays hymecromone and sorafenib alone were ineffective. Oral administration of hymecromone (50 to 200 mg/kg) plus sorafenib (30 mg/kg) eradicated Caki-1 tumor growth without toxicity. Hymecromone and sorafenib alone were ineffective. Conclusions: To our knowledge this is the first study to show that the combination of sorafenib and the nontoxic dietary supplement hymecromone is highly effective for controlling renal cell carcinoma. References 1 : Evaluation and management of the renal mass. Med Clin North Am2011; 95: 179. Google Scholar 2 : Defining an individualized treatment strategy for metastatic renal cancer. Urol Clin North Am2012; 39: 233. Google Scholar 3 : Integration of surgery and systemic therapy for renal cell carcinoma. Urol Clin North Am2012; 39: 211. Google Scholar 4 : Sorafenib in renal cell carcinoma. Crit Rev Oncol Hematol2011; 80: 314. Google Scholar 5 : Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther2011; 11: 825. Google Scholar 6 : The chemistry and occurrence of coumarins. In: Coumarins: Biology, Applications and Mode of Action. Edited by . New York: John Wiley & Sons1997: 23. Google Scholar 7 : Coumarins—multifaceted molecules with many analytical and other applications. In: Coumarins: Biology, Applications and Mode of Action. Edited by . New York: John Wiley & Sons1997: 303. Google Scholar 8 : Spasmolytic activity of some 4-methylumbelliferone derivatives. Boll Chim Farm1983; 122: 158. Google Scholar 9 : Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res2010; 70: 2613. Google Scholar 10 : Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J Biol Chem2004; 279: 48071. Google Scholar 11 : Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma. Cancer Res1989; 49: 3045. Google Scholar 12 : A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett2005; 579: 2722. Google Scholar 13 : Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Br J Cancer2011; 105: 1839. Google Scholar 14 : 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res2009; 315: 1914. Google Scholar 15 : Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol2008; 18: 288. Google Scholar 16 : Hyaluronan in human malignancies. Exp Cell Res2011; 317: 383. Google Scholar 17 : Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer2012; 118: 2394. Google Scholar 18 : A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice. Eur J Pharmacol2009; 614: 128. Google Scholar 19 : Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. Mol Cancer2011; 10: 30. Google Scholar 20 : 4-Methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol2006; 57: 165. Google Scholar 21 : Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res2011; 71: 4085. Google Scholar 22 : Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol2000; 163: 348. Link, Google Scholar 23 : Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem2006; 281: 34936. Google Scholar 24 : Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem2005; 280: 8875. Google Scholar 25 : Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther2009; 47: 61. Google Scholar 26 : VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res1999; 247: 495. Google Scholar 27 : HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res2010; 70: 10090. Google Scholar 28 : Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem2000; 275: 27641. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 190Issue 1July 2013Page: 285-290Supplementary Materials Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordscarcinoma, renal cellkidneyneoplasm invasivenesssorafenibhymecromoneMetricsAuthor Information Anaid Benitez Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida Equal study contribution. More articles by this author Travis J. Yates Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida Equal study contribution. More articles by this author N. Shamaldevi Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida More articles by this author Tim Bowen Section of Nephrology, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom More articles by this author Vinata B. Lokeshwar Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida Department of Urology, University of Miami-Miller School of Medicine, Miami, Florida Department of Cell Biology, University of Miami-Miller School of Medicine, Miami, Florida More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2045550424 created "2016-06-24" @default.
• W2045550424 creator A5008104501 @default.
• W2045550424 creator A5018342347 @default.
• W2045550424 creator A5036828039 @default.
• W2045550424 creator A5078000516 @default.
• W2045550424 creator A5085602878 @default.
• W2045550424 date "2013-07-01" @default.
• W2045550424 modified "2023-09-23" @default.
• W2045550424 title "Dietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma" @default.
• W2045550424 cites W1991463736 @default.
• W2045550424 cites W1997100416 @default.
• W2045550424 cites W1998000133 @default.
• W2045550424 cites W2026718707 @default.
• W2045550424 cites W2028385586 @default.
• W2045550424 cites W2030594691 @default.
• W2045550424 cites W2052715441 @default.
• W2045550424 cites W2053441326 @default.
• W2045550424 cites W2057694188 @default.
• W2045550424 cites W2058692868 @default.
• W2045550424 cites W2060609122 @default.
• W2045550424 cites W2069798828 @default.
• W2045550424 cites W2076585749 @default.
• W2045550424 cites W2089764697 @default.
• W2045550424 cites W2101433680 @default.
• W2045550424 cites W2101918466 @default.
• W2045550424 cites W2105341799 @default.
• W2045550424 cites W2132212967 @default.
• W2045550424 cites W2133328496 @default.
• W2045550424 cites W2161816270 @default.
• W2045550424 cites W2164416830 @default.
• W2045550424 cites W2170076211 @default.
• W2045550424 cites W2170379452 @default.
• W2045550424 cites W2325134704 @default.
• W2045550424 doi "https://doi.org/10.1016/j.juro.2012.12.011" @default.
• W2045550424 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5058418" @default.
• W2045550424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23228386" @default.
• W2045550424 hasPublicationYear "2013" @default.
• W2045550424 type Work @default.
• W2045550424 sameAs 2045550424 @default.
• W2045550424 citedByCount "18" @default.
• W2045550424 countsByYear W20455504242014 @default.
• W2045550424 countsByYear W20455504242015 @default.
• W2045550424 countsByYear W20455504242016 @default.
• W2045550424 countsByYear W20455504242017 @default.
• W2045550424 countsByYear W20455504242018 @default.
• W2045550424 countsByYear W20455504242019 @default.
• W2045550424 countsByYear W20455504242020 @default.
• W2045550424 countsByYear W20455504242021 @default.
• W2045550424 countsByYear W20455504242022 @default.
• W2045550424 countsByYear W20455504242023 @default.
• W2045550424 crossrefType "journal-article" @default.
• W2045550424 hasAuthorship W2045550424A5008104501 @default.
• W2045550424 hasAuthorship W2045550424A5018342347 @default.
• W2045550424 hasAuthorship W2045550424A5036828039 @default.
• W2045550424 hasAuthorship W2045550424A5078000516 @default.
• W2045550424 hasAuthorship W2045550424A5085602878 @default.
• W2045550424 hasBestOaLocation W20455504242 @default.
• W2045550424 hasConcept C126322002 @default.
• W2045550424 hasConcept C126894567 @default.
• W2045550424 hasConcept C143998085 @default.
• W2045550424 hasConcept C2777472916 @default.
• W2045550424 hasConcept C2777546739 @default.
• W2045550424 hasConcept C2778019345 @default.
• W2045550424 hasConcept C2778695046 @default.
• W2045550424 hasConcept C71924100 @default.
• W2045550424 hasConceptScore W2045550424C126322002 @default.
• W2045550424 hasConceptScore W2045550424C126894567 @default.
• W2045550424 hasConceptScore W2045550424C143998085 @default.
• W2045550424 hasConceptScore W2045550424C2777472916 @default.
• W2045550424 hasConceptScore W2045550424C2777546739 @default.
• W2045550424 hasConceptScore W2045550424C2778019345 @default.
• W2045550424 hasConceptScore W2045550424C2778695046 @default.
• W2045550424 hasConceptScore W2045550424C71924100 @default.
• W2045550424 hasIssue "1" @default.
• W2045550424 hasLocation W20455504241 @default.
• W2045550424 hasLocation W20455504242 @default.
• W2045550424 hasLocation W20455504243 @default.
• W2045550424 hasLocation W20455504244 @default.
• W2045550424 hasOpenAccess W2045550424 @default.
• W2045550424 hasPrimaryLocation W20455504241 @default.
• W2045550424 hasRelatedWork W1498185347 @default.
• W2045550424 hasRelatedWork W1995825359 @default.
• W2045550424 hasRelatedWork W2154171266 @default.
• W2045550424 hasRelatedWork W2161816270 @default.
• W2045550424 hasRelatedWork W2342063648 @default.
• W2045550424 hasRelatedWork W2378377904 @default.
• W2045550424 hasRelatedWork W2439773562 @default.
• W2045550424 hasRelatedWork W2517171178 @default.
• W2045550424 hasRelatedWork W2590369810 @default.
• W2045550424 hasRelatedWork W4250847356 @default.
• W2045550424 hasVolume "190" @default.
• W2045550424 isParatext "false" @default.
• W2045550424 isRetracted "false" @default.
• W2045550424 magId "2045550424" @default.
• W2045550424 workType "article" @default.